Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Global RNA Analysis Market Size, Share & Industry Trends Analysis Report By Product, By Technology (Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology), By End-use, By Application, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.
Research on RNA analysis spans a broad spectrum of issues, from an in-depth examination of the transcriptome of the entire collection of RNA transcripts encoded by a genome to examining the effects of individual short noncoding RNAs on particular genes. The method used to produce RNA in a lab setting from a DNA template is known as in vitro transcription.
For use in procedures like in vitro translation, the investigation of RNA viruses, and RNA: protein interaction investigations, RNA is produced from DNA templates using in vitro transcription devices. For use in RNA analysis research, single-stranded RNA probes, microgram amounts of specified RNA transcripts, and antisense RNA are all prepared using riboprobe systems.
RNA sequencing (RNA-Seq) makes use of high-throughput sequencing techniques to shed light on a cell's transcriptome. RNA-Seq offers far larger coverage and better resolution of the dynamic of the transcriptome than earlier Sanger sequencing- and microarray-based approaches. The data produced by RNA-Seq enable the discovery of novel transcripts, recognition of alternatively spliced genes, and detection of allele-specific expression in addition to quantifying gene expression.
Researchers have been able to better understand the functional intricacy of the transcription due to recent improvements in the RNA-Seq methodology, which includes sample preparation, library creation, and data analysis. RNA-Seq can be used to explore several RNA populations, including total RNA, pre-mRNA, and noncoding RNA, such as microRNA and long ncRNA, in addition to polyadenylated messenger RNA (mRNA) transcripts.
An overview of RNA-Seq methodologies, including applications, experimental planning, and technological difficulties. The fundamental tenet of molecular biology describes the progression of information from DNA encoded in genes to RNA that is translated into proteins. The phenotype of an organism is the final manifestation of this genetic information altered by environmental circumstances.
COVID-19 Impact Analysis
Due to Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), there is a rising demand for testing and diagnosis during the COVID 19 pandemic, which is anticipated to propel market expansion. Since COVID-19 is an infectious disease, its prevalence will likely increase during the predicted period.
To analyze and examine the infection, RNAs are isolated from the BAL-Bronchoalveolar Lavage Fluid of the COVID patient. This is being used to offer therapeutic guidance on anti-inflammatory drugs and to comprehend the host and response's molecular architectures better to create effective therapies. As a result, the demand for diagnostics and research is rising, which is likely to fuel market expansion.
Market Growth Factors
Demand For Personalized Medication Is Rising
The identification, classification, and treatment of many diseases are being changed by personalized medicine, which has emerged as a major topic of research in the healthcare sector. These developments are especially noticeable in RNA analysis.
The number of tailored medications, therapies, and diagnostic tools has grown since 2006, and this trend is anticipated to continue in the years to come, according to a 2017 report by the Personalized Medicine Coalition. Personalized medicine is the practice of tailoring a patient's medical care to their particular needs.
Greater Emphasis On Biomarker Discovery
For determining the toxicity and efficacy of medications, biomarker identification and its clinical applications have streamlined the drug discovery and development process. Additionally, biomarkers are essential in providing a better understanding of the disease route and progression for conditions like cancer, CVD, and neurological disorders. Pharmaceutical and biotechnology businesses run extremely sophisticated and expensive drug development operations.
Market Restraining Factors
High Capital Expenditures Along With Lack Qualified Professionals
With the widespread use of novel applications, RNA Analysis research is now used for everything from the identification of new drugs, vaccines, and diagnostic targets to toxicology, the identification of surrogate markers of activity in clinical research, and the capacity to provide details on the mechanisms of drug action. It is also used to identify surrogate markers of activity in other fields. This adds to the high cost of analytics by requiring the use of many platforms, devices, and laboratory documentation systems.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2018, Jun - 2022, Jun) Leading Players
Chapter 4. Global RNA Analysis Market by Product
4.1 Global Kits & Reagents Market by Region
4.2 Global Instruments Market by Region
4.3 Global Services Market by Region
Chapter 5. Global RNA Analysis Market by Technology
5.1 Global Real Time-PCR (qPCR) Technology Market by Region
5.2 Global Sequencing Technology Market by Region
5.3 Global Microarray Technology Market by Region
5.4 Global Others Market by Region
Chapter 6. Global RNA Analysis Market by End-use
6.1 Global Government Institutes & Academic Centers Market by Region
6.2 Global Hospitals & Clinics Market by Region
6.3 Global Pharmaceutical & Biotechnology Companies Market by Region
6.4 Global Contract Research Organizations (CROs) Market by Region
Chapter 7. Global RNA Analysis Market by Application
7.1 Global Infectious Diseases & Pathogenesis Market by Region
7.2 Global Epigenetics Market by Region
7.3 Global RNA Structure & Molecular Dynamics Market by Region
7.4 Global Development & Delivery of RNA Therapeutics Market by Region
7.5 Global Construction of RNA Expression Atlas Market by Region
7.6 Global Alternative RNA Splicing Market by Region
7.7 Global Others Market by Region
Chapter 8. Global RNA Analysis Market by Region
Chapter 9. Company Profiles
9.1 F. Hoffmann-La Roche Ltd.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Acquisition and Mergers:
9.2 Danaher Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Agilent Technologies, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Product Launches and Product Expansions:
9.3.5.3 Acquisition and Mergers:
9.4 Thermo Fisher Scientific, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Product Launches and Product Expansions:
9.4.5.3 Acquisition and Mergers:
9.5 Qiagen N.V.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Product Launches and Product Expansions:
9.6 Illumina, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.6.5.3 Acquisition and Mergers:
9.7 Bio-Rad laboratories, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Product Launches and Product Expansions:
9.8 Eurofins Scientific Group
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Recent strategies and developments:
9.8.4.1 Product Launches and Product Expansions:
9.9 Merck Group
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. Promega Corporation
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Product Launches and Product Expansions:
9.10.2.2 Geographical Expansions
For more information about this report visit https://www.researchandmarkets.com/r/7g9of7
Attachment
